Rick E. Winningham - 28 Feb 2025 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Brett A. Grimaud, Attorney-in-Fact
Issuer symbol
TBPH
Transactions as of
28 Feb 2025
Net transactions value
+$20,364
Form type
4
Filing time
04 Mar 2025, 18:17:21 UTC
Previous filing
24 Feb 2025
Next filing
22 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TBPH Ordinary Shares Award $20,364 +2,178 +0.12% $9.35 1,778,144 28 Feb 2025 Direct F1
holding TBPH Ordinary Shares 3,900 28 Feb 2025 As Custodian
holding TBPH Ordinary Shares 92,567 28 Feb 2025 By Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects an acquisition from the Issuer pursuant to a restricted share purchase agreement under the Issuer's Amended and Restated 2013 Equity Incentive Plan at a per-share price equal to the closing per-share price of the Issuer's ordinary shares on the Nasdaq Global Market on February 28, 2025.